Features
Get A Demo
Plans
Sign Up
Login
All Federal Contract IDV Awards
Help
Indefinite Delivery Contract HHSN272201600008I
Award Date
7/15/16
Last Date to Order
7/14/23
Overview
🤔 AI Insights
Buyer Personas
Industry Personas
Buyer Personas In this Market
Activity
5
Contract IDVs
Contract Awards
26
Transactions
9
Price Lists
Opportunity Stack
1
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Advanced Bioscience Laboratories, Inc.
Ultimate Awardee
Not listed
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
PSC Category
AN81 - R&D- Medical: Aids Research (Basic Research)
Federal Contract Vehicle
HIV Microbicides and Biomedical Prevention 2016-2021
Pricing Type
Cost Plus Fixed Fee
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
HIV Microbicides and Biomedical Prevention 2016-2021
Master IDIQ
HHSN272201600008I
Indefinite Delivery Contract
26
Federal Contract Awards
Description
Update #1
Update #2
Update #3
COMPREHENSIVE RESOURCES FOR HIV MICROBICIDES AND BIOMEDICAL PREVENTION
Posted 7/15/16, 12:00 AM
Mod #
Description
Reason For Modification
Federal Obligation
(Click to sort descending)
Date
(Click to sort ascending)
P00008
COMPREHENSIVE RESOURCES FOR HIV MICROBICIDES AND BIOMEDICAL PREVENTION
Other Administrative Action
$0
6/22/23
P00007
THE PURPOSE OF THIS CONTRACT IS TO PROVIDE THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES WITH A COMPREHENSIVE SUITE OF PRECLINICAL PRODUCT DEVELOPMENT SERVICES FOR CANDIDATE PRODUCTS THAT EMERGE FROM INVESTIGATOR-INITIATED RESEARCH STUDIE
Other Administrative Action
$0
8/16/22
P00006
EO14042 - THE PURPOSE OF THIS CONTRACT IS TO PROVIDE THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES WITH A COMPREHENSIVE SUITE OF PRECLINICAL PRODUCT DEVELOPMENT SERVICES FOR CANDIDATE PRODUCTS THAT EMERGE FROM INVESTIGATOR-INITIATED RESEARCH STUDIE
Other Administrative Action
$0
10/15/21
P00005
THE PURPOSE OF THIS CONTRACT IS TO PROVIDE THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES WITH A COMPREHENSIVE SUITE OF PRECLINICAL PRODUCT DEVELOPMENT SERVICES FOR CANDIDATE PRODUCTS THAT EMERGE FROM INVESTIGATOR-INITIATED RESEARCH STUDIE
Other Administrative Action
$0
8/18/20
P00004
THE PURPOSE OF THIS CONTRACT IS TO PROVIDE THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES WITH A COMPREHENSIVE SUITE OF PRECLINICAL PRODUCT DEVELOPMENT SERVICES FOR CANDIDATE PRODUCTS THAT EMERGE FROM INVESTIGATOR-INITIATED RESEARCH STUDIE
Other Administrative Action
$0
1/14/20
Name
Description
Awardee
Potential Value
(Click to sort descending)
Award Date
(Click to sort descending)
Completion Date
(Click to sort descending)
Updated At
(Click to sort descending)
Delivery Order HHSN272201600008I-75N93020F00004
This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL). The contract, valued at $239,850.00, is a Delivery Order issued under the HIV Microbicides and Biomedical Prevention 2016-2021 master IDIQ vehicle. ABL, a contract research and manufacturing organization, will assist NIAID in planning and implementing two meetings focused on pediatric formulations and ways to leverage private sector resources for HIV microbicide and biomedical prevention research. This is a cost-plus-fixed-fee contract with a completion date of August 31, 2024. The contract does not have a set-aside designation.
Advanced Bioscience Laboratories, Inc.
$239.9k
9/1/20
8/31/24
7/24/23
Delivery Order HHSN272201600008I-75N93020F00001
This cost-plus-fixed-fee delivery order, valued at one million three hundred ninety-three thousand seven hundred twenty-two dollars ($1,393,722), was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Advanced Bioscience Laboratories, Inc. of Potomac, Maryland. The order is placed against the HIV Microbicides and Biomedical Prevention 2016-2021 master IDIQ contract to perform quality evaluation and documentation of study products to certify their regulatory compliance for use in HIV microbicide clinical trials. This will ensure manufacturing processes are well-documented and result in reliable data to advance the Comprehensive Resources for HIV Microbicides and Biomedical Prevention program's goal of developing safe and effective prevention methods. No subcontractors or set-aside designations were identified. Work will be completed by July 2022.
Advanced Bioscience Laboratories, Inc.
$1.4m
5/1/20
4/30/22
1/12/22
Delivery Order HHSN272201600008I-HHSN27200007
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL) for the "NONHUMAN PRIMATE PURCHASE AND HOLDING" program. The $9,557,449.93 cost-plus-fixed-fee contract is a delivery order issued under the larger "HIV Microbicides and Biomedical Prevention 2016-2021" indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. The contract does not have a set-aside designation. ABL is a leading contract research and manufacturing organization that specializes in developing gene therapies, vaccines, oncolytics, and immunotherapies, particularly supporting infectious disease research and product development initiatives for government agencies.
Advanced Bioscience Laboratories, Inc.
$9.6m
6/29/17
6/30/20
6/18/24
Delivery Order HHSN272201600008I-HHSN27200002
PLANNING AND IMPLEMENTATION OF A NIAID CONSULTATION: ADVANCING DEVELOPMENT OF MULTIPURPOSE PREVENTION TECHNOLOGIES (MPT).
Advanced Bioscience Laboratories, Inc.
$174.1k
8/25/16
9/14/17
9/7/23
Delivery Order HHSN272201600008I-HHSN27200006
This is a cost-plus-fixed-fee delivery order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL). The $533,028.94 contract is for the development of HIV non-vaccine biomedical prevention products, including assessing product attributes, positioning, and messaging to drive adoption and use of new personal use products among young, urban and peri-urban South African women. The contract is not set aside and is part of the larger "HIV Microbicides and Biomedical Prevention 2016-2021" IDIQ vehicle. ABL is a contract research and manufacturing organization specializing in biologics development, with extensive experience supporting NIH and HHS agencies through prime and subcontracts, including manufacturing, testing, and assay services for vaccine and therapeutic candidates.
Advanced Bioscience Laboratories, Inc.
$533.0k
4/26/17
4/30/18
9/7/23
Name
Description
Solicitation Number
Federal Agency
Type
Posted Date
(Click to sort descending)
Comprehensive Resources for HIV Microbicides and Biomedical Prevention
Added: Jun 24, 2015 7:59 am Presolicitation Notice InformationThe development of highly effective HIV prevention strategies, including a preventive vaccine and other non-vaccine biomedical prevention (nBP) products, remains one of the highest priorities for the Division of AIDS (DAIDS) and the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). With current global HIV infection estimates exceeding 33 million people, the development of safe, effective, and acceptable nBP products to prevent the sexual transmission of HIV could play a major role in the worldwide reduction of the estimated 5000 new HIV infections per day.These services are currently provided by two NIAID contracts entitledThis is a recompetition of two existing contracts, "Non-human Primate Models to Evaluate Therapeutic Strategies and Topical Microbicides for HIV" (under Contractwith Advanced BioScience Laboratories, Inc. under contract numberNo. HHSN272200800020C with Advanced BioScience Laboratories) and , and "Comprehensive Resources for HIV Microbicides and Biomedical Prevention" (with Advanced BioScience Laboratories, Inc. under cContract numberNo. HHSN272201000001C with Advanced Bioscience Laboratories). However, the Government intends to consolidate these services into one requirement under one contract.The Government intends to award multiple-award Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts in order to continue these support services. Task Orders will be issued in the following areas:• Preclinical gap-filling services (Task Area A)• HIV animal models supporting product development (Task Area B)• Bioanalytical support services (Task Area C)• Product manufacturing (Task Area D)• Scientific and quality/regulatory support services (Task Area E)It is anticipated that NIAID will award base contract awards to multiple contractors for Task Areas A, B, C, and D; however, NIAID anticipates awarding a base contract to a single contractor for Task Area E. In order to ensure the independence and objectivity required for the functions carried out under Task Area E, the contractor who is selected for the award of Task Area E will not be awarded a base contract for Task Areas A, B, C, and/or D. This includes both the Prime Contractor as well as any potential Subcontractor(s).The purpose of the proposed contract is to provide NIAID with preclinical product development services for candidate products that emerge from investigator-initiated research studies or from collaborations with outside companies or organizations. The scope of work encompasses preclinical activities that range from initial product discovery to those required to support clinical trials and/or product licensure. More specifically, these development services may be used to support a product at any point along the product development pathway, from discovery to IND, Investigational Device Exemption (IDE), and/or New Drug Application (NDA) filings with the Food and Drug Administration (FDA). NIAID will primarily use this contract to more rapidly and efficiently fill critical development gaps and advance promising nBP products and MPTs into clinical testing. Although the focus of this contract will be development of nBP products, contract resources, at the discretion of NIAID, may be used to advance HIV vaccines, antivirals, or other HIV preventive or therapeutic strategies. Throughout this contract, these candidate products and/or strategies will collectively be referenced as "products."Project RequirementsOfferors should have the qualifications, experience and capability to perform this requirement. The Contractor will carry out tasks in the following five areas:A. Preclinical Gap-Filling Services: Under this task area, the Contractor shall conduct the following types of activities: 1) In vitro/ex vivo assays or methods; 2) Small and large animal safety models; and 3) Other specific activities in support of this task area as required by NIAID to advance products into clinical testing.B. HIV Animal Models Supporting Product Development: Under this task area, the Contractor shall conduct pharmacokinetic (PK), safety, and efficacy studies in animal models of mucosal HIV/SIV/SHIV transmission in order to characterize promising products, inform dose selection, optimize formulations, and/or obtain other information necessary to advance or support product testing in subsequent animal or human studies. These models may include nonhuman primates (NHP), humanized mice, or other animal models of HIV infection or pathogenesis as they become available. When applicable, other activities (e.g., immunology, histopathology, etc.) as specified in the Task Order SOW shall be performed.C. Bioanalytical Support Services: Under this task area, the Contractor shall conduct the following types of activities to support product development and fulfill regulatory requirements: 1) Analytical method development, method transfer and validation, and/or performance of the method; and 2) Other specific activities in support of this task area as required by FDA to advance products into clinical testingD. Product Manufacturing: Under this task area, the Contractor shall conduct the following types of activities: 1) Product manuafacturing and/or characterization to support both preclinical and clinical product indications.; and 2) Other specific activities in support of this task area as required by FDA to advance prducts into clinical testing.E. Scientific and Quality/Regulatory Support Services: Under this task area, the Contractor shall perform the following types of activities to advise and support the COR, other NIAID staff, and/or product sponsors, or support the general development of products through provision of resources to the HIV prevention field: 1) Provide additional expertise; 2) Develop and support programmatic meetings in specific regulatory requirements or other topics; 3) Provide Quality Assurance/Quality Control (QA/QC) support; 4) Conduct audits; 5) Prepare regulatory documentation; 6) Convene scientific groups related to non-vaccine biomedical prevention (nBP) products in support of this contract; and 7) Provide centralized storage for contract materials.Anticipated Period of PerformanceIt is anticipated that multiple Indefinite Delivery/Indefinite Quantity (ID/IQ) type contracts will be awarded on or about June 15, 2016 for a period of 7 years through June 14, 2023. Task Orders to be issued against the base contract will primarily be cost-reimbursement type, both term and completion form. The Government reseves the right, however, to issue fixed price type Task Orders, when appropriate.Upon award of the base contract, the Government anticipates awarding a Task Order as follows:1) Task Order #E-001, Quality Assurance/Quality Control Support. The period of performance will be for a one (1) year (Base Period), plus six one-year options (terms) that may be exercised by the Government unilaterally, for a total possible performance period of seven (7) years, beginning on or about June 15, 2016. The requirement will be for the delivery of 2.05 full time equivalents (FTEs) per year for the base period (Year 1) and 2.05 FTEs per year for Options 1-6 (Years2-7).Any responsible offeror may submit a proposal which will be considered by the Agency. This RFP will be available electronically on/about July 10, 2015, and may be accessed through FedBizOpps http://www.fedbizopps.gov/ and the NIAID Office of Acquisition (OA) Home Page at http://www.niaid.nih.gov/contract. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.
NIAID-DAIDS-NIHAI2015029
Department of Health and Human Services National Institutes of Health
Award Notice 1/1
6/24/15, 7:59 AM